Endra Life Sciences Inc. insider trading

Every open-market purchase and sale by Endra Life Sciences Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Endra Life Sciences Inc.’s insiders pay?

From October 24, 2018 to May 22, 2023, 7 insiders reported 7 open-market purchases and 2 sales not made under a pre-set plan in Endra Life Sciences Inc.

Endra Life Sciences Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Thornton Michael Milos	Chief Technology Officer	2	—	—	0	—	May 22, 2023
Wells David R.	Chief Financial Officer	2	—	—	0	—	September 30, 2019
Basenese Lou	Director	0	—	—	1	—	August 27, 2021
Digiandomenico Anthony	Director	1	—	—	0	—	May 3, 2023
Harsh Michael	Director	1	—	—	0	—	June 10, 2019
Longboard Capital Advisors, LLC	10% owner	0	—	—	1	—	October 24, 2018
Tokman Alexander Y	Director	1	—	—	0	—	May 17, 2022

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Endra Life Sciences Inc. · Funds · Politicians